the new generation glocalized patient network in theragenomic and personalized medicine and individualized drug safety
June 30, 2021 – This post is based on an overview given by the Centers of Disease Control (CDC) of the United States on the current knowledge on the occurrence of severe adverse effects (SAE) after anti-Covid-19 vaccination as reported …
Serious adverse events after Covid-19 vaccination occur but are very rare Read more »
January 26, 2021 –Â To date, a rare serious adverse (drug) reaction (SADR) has been noted to be associated with the first two Covid-19 vaccines, i.e., the one from Pfizer-BioNTech and the one from Moderna. We are talking about anaphylaxis, which …
Rare cases of anaphylaxis with COVID-19 vaccines Read more »
October 31, 2018 – The American Food and Drug Administration (FDA) Â recently approved Cemiplimab-Rwlc (Libtayo) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for …
December 23, 2014 – The U.S. Food and Drug Administration (FDA) just approved Saxenda (liraglutide [rDNA origin] injection) as a treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity. The drug is approved for use …
The weight-management drug Liraglutide (Saxenda) has just been approved by the FDA Read more »
March 19, 1014 – We just learned from a recent Press Release by the American Food and Drug Administration (FDA) on the approval of Metreleptin [Myalept] to treat leptin deficiency. Read the article below: On February 24, 2014, the U.S. …
FDA approves Metreleptin [Myalept] to treat rare metabolic disease Read more »
![FDA has approved Pertuzumab [Perjeta] in combination with Trastuzumab [Herceptin] and docetaxel chemotherapy for the treatment of people with HER2-positive metastatic breast cancer](https://thasso.com/wp-content/uploads/2012/06/Breast-Cancer-II-African-II.png)
June 11, 2012 – The American Food and Drug Administration (FDA) has approved Pertuzumab [Perjeta].  Pertuzumab [Perjeta] is approved in combination with Trastuzumab [Herceptin]  and docetaxel chemotherapy for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have …
June 12, 2012 — Two diagnostic tests to identify HER2-positive breast cancer have been approved by the US Food and Drug Administration (FDA) for use as companion diagnostics for the new targeted therapy Pertuzumab [Perjeta]. The tests — HercepTest and …
New Breast Cancer HER2 Diagnostic Tests Approved by FDA Read more »